US Bioservices Dispensing Newly Approved ALECENSA

January 30, 2016

The U.S. Food and Drug Administration recently approved Genentech's ALECENSA (alectinib) to treat people with advanced (metastatic) ALK-positive non-small cell lunch cancer (NSCLC) whose disease has worsened.